NCT06468215View on ClinicalTrials.gov

Fertility Sparing Therapy for Patients With Stage IA G2 Endometrial Cancer

NANot yet recruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

July 31, 2024

Primary Completion Date

July 31, 2028

Study Completion Date

October 31, 2028

Conditions
Carcinoma, EndometrioidFertility Preservation
Interventions
DRUG

Treatment Option 1 is a single-drug regimen, with oral medroxyprogesterone acetate (MPA) 500mg/d or MA 320mg/d.

Compare the efficacy of mono-therapy with progesterone versus combined therapy to determine the best treatment option.

All Listed Sponsors
lead

Peking University People's Hospital

OTHER

NCT06468215 - Fertility Sparing Therapy for Patients With Stage IA G2 Endometrial Cancer | Biotech Hunter | Biotech Hunter